| INTRODUCTION
Cirrhosis is an increasing cause of morbidity and mortality in developed countries. It is now the fifth leading cause of death in the UK and the 13th worldwide. 1, 2 The progression of cirrhosis is characterised by significant intra-and extrahepatic microvascular alterations and dysregulation. A dysfunctional microcirculation leads to regions of heterogeneous microvascular flow which causes tissue hypoxia. In turn, this creates worsening microcirculatory dysfunction and ultimately a downward spiral ensues eventually leading to organ failure and death. 3 The structural and dynamic changes that occur in the microcirculation of cirrhotic patients are widespread. Within the liver, the hepatic microvasculature demonstrates increased intrahepatic resistance, and these results in portal hypertension and circulatory dysfunction. [4] [5] [6] While the systemic haemodynamic dysfunction of cirrhosis is well characterised, the extra hepatic microcirculation in cirrhosis has been less widely studied. Initial reports have shown heterogeneous alterations and microcirculatory dysfunction in extrahepatic vascular beds, 7 however, the extent of microcirculatory abnormalities and the impact this may have in the pathogenesis of organ failure in end stage liver cirrhosis is yet to be determined.
In the intensive care setting, technological advancements in hand held videomicroscopes have made feasible the monitoring and quantification of the microcirculation at the bedside. Certainly, within the context of the critically ill, derangements in the microcirculation are frequently encountered, and a direct correlation is seen between the degree of microvascular dysfunction present, and the development of multiple organ failure in sepsis. [8] [9] [10] Given the importance of restoring a homogenous microvascular flow in septic patients, a number of recent studies have focused on the effect of pharmacological agents on the microvasculature. These studies have shown that despite restoration of systemic haemodynamics with vasopressor agents there is often not a parallel improvement in the microcirculatory alterations, leading to a loss of systemic and microcirculatory coherence. Vasoactive pharmacological agents are also commonly used to treat cirrhosis and its associated complications, especially in the context of variceal bleeding and renal impairment. Unfortunately however, not all patients respond to exogenously administered vasoconstrictors, and certainly the microvascular response to these agents is poorly defined.
This article therefore provides an update on the role of the microcirculation in the pathophysiology of cirrhosis and its associated complications. We review the literature on the study of the microcirculation in the liver parenchyma and extrahepatic regional tissue beds. Furthermore, we describe some of the microvasculature imaging techniques enabling real time monitoring of the microcirculation in vivo, knowledge of which may advance our comprehension of the mechanistic action of therapeutic agents and potentially guide future treatment modalities within this field of interest.
| TH E MICROCIRCULATION

| Anatomy and regulation
At the tail end of the oxygen cascade, and ultimately regulating tissue blood flow to match micro-regional oxygen demand, lies the largest "organ" in the body-the microcirculation. 11 Anatomically it consists of a network of blood vessels less than 100 lm in diameter including arterioles, capillaries, post-capillary venules and the blood flowing within these vessels. 12 The structure (and function) of the microcirculation is highly heterogeneous between different organ systems. Arterioles, arising after the original artery has entered an organ and bifurcated up to eight times, continue to subdivide until vessel cross-sectional diameter is <20 lm. Below this size, flow continues through capillaries wherein the microvessels' diameter is only marginally larger than the erythrocytes flowing within them in single file (8-10 lm) . Blood is drained away from capillaries through increasingly enlarging postcapillary venules.
Functionally the microcirculation serves to transport oxygen and nutrients to tissue cells, and to remove carbon dioxide and other products of metabolism. In addition, it plays a role in immunological function and temperature regulation, in modulating the distribution of fluid between the intravascular and extravascular compartments, and in delivering therapeutic agents to target cells. 3, 13 Capillary blood flow is determined by the hydrostatic driving pressure, haemorheology, capillary patency and arteriolar tone. Regulation of microcirculatory vascular tone, ultimately determining capillary patency, can be viewed as a three-tier hierarchy; autoregulation (lower tier), intrinsic regulation (middle tier) and extrinsic regulation (top tier) 12 ( Figure 1 and local paracrine secretions (histamine, serotonin, thromboxane
[Tx]). Extrinsic regulation allows the central nervous system to exert control of the microcirculation through neurohormonal mechanisms.
The hepatic microcirculation is unique due to the dual blood supply of the liver. After repeated branching, the hepatic arterioles and portal venules supply blood to the hepatic sinusoids. These correspond to the capillary bed of the liver, and are the location where transport of nutrients and removal of waste products takes place.
The hepatic arterioles wind themselves around the portal venules, and it has been demonstrated that communication occurs between the vessels. In conditions of reduced portal venous flow blood is shunted via hepatic arteriolo-portal anastomoses to maintain microvascular perfusion and oxygen delivery. 14 Sinusoids run straight between the liver cells, and these are lined with specialised endothelial cells characterised by flattened processes perforated with small fenestrae, and the absence of a basement membrane. 15 Hepatic stellate cells (HSC) are located external to the endothelium in the space of Disse, a space between the hepatocytes and endothelium, and by acting as contractile machinery they play an important role in regulating vessel calibre and thus blood flow. 16 After passing through the sinusoids, blood flows into terminal central veins which combine and reach the hepatic vein.
| Intrahepatic microcirculation
In liver cirrhosis, marked changes occur within the intrahepatic microcirculation causing disruption to the normal regulatory mechanisms and ultimately leading to an increase in intrahepatic vascular resistance and portal hypertension. [4] [5] [6] The rise in sinusoid resistance is due to both mechanical factors relating to microvascular structural changes, and dynamic factors including endothelial dysfunction, reduced NO production, increased release of vasoconstrictor products and contraction of HSC. This results in an impairment of oxygen diffusion from the sinusoidal vessels to the liver parenchyma. 25 HSC are also involved in the pathological structural changes during sinusoidal remodelling. They migrate and promote coverage of sinusoidal vessels leading to vasoconstriction which contributes to the high vascular resistance. 26 Deposition of collagen in the space of Disse leads to narrowing and distorting the sinusoidal lumen, further restricting microvascular flow. 14 As a result of these changes, the liver tissue becomes hypoxic and an accumulation of hypoxia-inducible factors stimulates the production of angiogenic growth factors such as vascular endothelial growth factor (VEGF). 27, 28 The up regulation of VEGF not only leads to angiogenesis, but also stimulates activation and migration of HSC which induces an inflammatory response and further enhances the process. [29] [30] [31] Angiogenesis results in new vessel formation and shunting between pre-and post-sinusoidal vessels. 17 A rise in portal vein pressure is seen due to inadequate dilatation of poorly compliant abnormal intrahepatic neo-angiogenic vessels. 32 The new vessels themselves also further perpetuate the inflammatory response by expressing adhesion molecules and chemokines promoting the recruitment of inflammatory cells. 25 Sinusoidal endothelial cells normally release vasoactive substances to maintain sufficient flow. In liver cirrhosis, an imbalance occurs leading to impaired vasorelaxation-a process referred to intrahepatic endothelial dysfunction. 20 NO has been recognised as the main endothelial vasodilator of the sinusoidal microcirculation. 21 In cirrhosis, NO levels in the intrahepatic microcirculation have been shown to be insufficient to prevent excessive vasoconstriction and increased hepatic vascular tone. 22 The reduced bioavailability of NO is the hallmark of endothelial dysfunction and is due to decreased endothelial NO synthase (eNOS) activity resulting from oxidative stress, regulatory defects and increased level of eNOS inactivators. 23, 33 Although NO has been shown to be the primary molecule involved in vasodilation, there are number of other endothelial dilators identified to be deficient in cirrhosis and an increased release of vasoconstrictive mediators such as TxA2 and ET-1. 23 
| Splanchnic microcirculation
The enhanced intrahepatic resistance leads to a rise in portal pressure and a reduction in hepatic perfusion. Maladaptive splanchnic vasodilatation occurs in an attempt to restore hepatic perfusion increasing blood inflow with a resultant rise in portal pressure.
Rather than improving hepatic perfusion, this hyperaemia and portal hypertension ultimately leads to the development of a collateral circulation and porto-systemic shunting. An interesting concept relating to this was put forth by Newby and Hayes. 34 They proposed that as an increased cardiac output. 5 This hyperdynamic circulation increases portal venous inflow further, further exacerbating portal hypertension and splanchnic steal of blood contributing the development of hepatorenal syndrome (HRS) and multiple organ dysfunction. [35] [36] [37] [38] [39] The mechanisms responsible for splanchnic vasodilatation have been extensively investigated, and as with the sinusoidal microcirculation, NO is considered to be the pivotal factor. NO bioavailability is increased at the level of the splanchnic microvasculature in patients with cirrhosis and portal hypertension, mostly because of an increased activity of eNOS. 40 This upregulation of eNOS is classically thought to be triggered by an increase in portal pressure leading to circumferential vascular stretch in the splanchnic microcirculation activating the production of VEGF and eNOS. 41 to regulatory mechanisms. 8, 54, 55 The resultant microcirculatory dysfunction is characterised by heterogeneous abnormalities in blood flow and a regional mismatch in oxygen demand and supply, 10 and this has been associated with worsening clinical outcomes and organ failure.
9,55
Multiorgan dysfunction is commonly seen in decompensated cirrhosis, acute-on-chronic liver failure (ACLF), and in sepsis, and there is increasing evidence that the underlying pathophysiological mechanisms may be similar. The systemic inflammation hypothesis proposes that decompensation of cirrhosis occurs in the setting of severe systemic inflammation and oxidative stress. 42 Recent findings published by the CANONIC study group 56 strongly support the hypothesis, and indicate that systemic inflammation is the cause of decompensation in cirrhosis. The main mechanism of inflammation is translocation of bacteria, albeit without overt infection, and the spread of pathogen-associated molecular patterns (PAMPs).
57,58
PAMPs interact with immune cells and epithelia stimulating intracellular signalling pathways, leading to the expression of genes encoding inflammatory molecules. 42 Evidence from sepsis demonstrates high levels of circulating inflammatory mediators, and reactive oxygen species, cause deleterious effects on microcirculatory homoeostasis, microcirculatory thrombosis, mitochondrial and cell dysfunction, ultimately leading to cell death. 59, 60 The picture of advanced cirrhosis could therefore be described as a systemic inflammatory multiorgan syndrome with associated haemodynamic disturbance, bearing a close resemblance to sepsis.
In view of the vascular abnormalities and systemic inflammation present in cirrhosis, it is logical to hypothesise that extrahepatic microvascular alterations exist, and that they play a key role in the pathogenesis of multiple organ failure. Notably, however, a dissociation between microvascular perfusion and global haemodynamic variables has been well documented, 10, [61] [62] [63] as has the heterogeneity of the microvasculature within different organ systems. 10, 64 Accordingly, this makes drawing conclusions about various pathophysiological states difficult to achieve, though direct visualisation of the microcirculation in vivo can aid this.
| Peripheral microcirculation
The sublingual microcirculation was evaluated in cirrhotic patients with and without sepsis using sidestream dark field (SDF) imaging by Sheikh et al 7 They found that microvascular perfusion was significantly impaired in decompensated cirrhotic patients when compared to compensated cirrhotic patients secondary to vasoconstriction. Furthermore, they also demonstrated that the sublingual microcirculation in patients with decompensated liver cirrhosis had a very similar appearance to one with sepsis, lending support to the systemic inflammation hypothesis. Activation of inflammation is key in the pathogenesis of microvascular alterations in sepsis, and high plasma levels of inflammatory cytokines such as TNF-a, interleukin (IL)-1, IL-6 and key regulatory cytokines (G-CSF and GM-CSF) promoting activation of monocytes and neutrophils, are present in decompensated cirrhosis. 57, 59, 65, 66 ACLF is a recently recognised syndrome, characterised by acute decompensation of cirrhosis, multiorgan failure and high short-term mortality. 67 Within ACLF, cytokines and chemokines involved in the innate, rather than adaptive, immune system are upregulated. This suggests that a dysregulated immune response leading to microcirculatory dysfunction, may be the predominant pathophysiological mechanism in the progression from decompensated cirrhosis to organ failure. 57 In sepsis, there is heterogeneous expression of inducible NO synthase (iNOS), 68 a substance found to be elevated in cirrhosis 69 and implicated in the development of pulmonary microvascular alterations, 70 which is thought to result in pathological shunting of blood flow in the microvasculature. Impaired red cell deformability leading to enhanced aggregation has been identified in both conditions, 71, 72 as has increased leucocyte and platelet rolling, and adhesion to the endothelial surface possibly impairing circulation of other cells.
25,73
A second study utilised SDF imaging to investigate the effect of age, diabetes, cirrhosis and chronic kidney disease on sublingual microvascular flow. 74 Toll-like receptor 4 (TLR4) has been identified as playing an important role in HRS, and it is overexpressed in the kidney tissue and urine in cirrhotic patients with acute kidney injury. 80 TLR4 is activated by PAMPs, upregulating the release of inflammatory mediators which induce endothelial and microcirculatory disruption. 81 Endothelial dysfunction at a microvascular level is associated with a reduction in renal vasodilator production demonstrated by decreased urinary excretion of prostaglandin (PG)E2, 6-keto PGF1a (a PGI 2 metabolite) and kallikrein. 82, 83 This imbalance between the activity of systemic vasoconstrictor systems and renal production of vasodilators favours vasoconstriction. 84 Renal hypoperfusion ensues which is further amplified by the stimulation of intrarenal vasoconstrictors including ET-1 and angiotensin. 85 Terlipressin is used in HRS as it has a much greater effect on vascular vasopressin receptors (V 1 ) than renal vasopressin receptors (V 2 ), thereby reducing the steal into the splanchnic circulation, and diverting blood to the systemic and renal circulations, improving
renal function in around 50% of patients. 86 The ultimate aim of restoring renal tissue perfusion is related more to microvascular perfusion than arterial blood flow, 87 
| Cerebral microcirculation
Cerebral haemodynamic derangement is well known in hepatic failure, and it is generally accepted that cerebral blood flow decreases in patients with liver cirrhosis. 89 Hepatic encephalopathy (HE) is a common complication of advanced cirrhosis and carries a very poor prognosis. 90 Multiple pathophysiological pathways, mostly related to ammonia metabolism, are involved in the development of HE.
Mounting evidence also suggests that abnormal cerebral haemodynamics, and a loss of cerebral autoregulation, plays a key role in the pathophysiology. The increase in CVR is likely to be secondary to microvascular dysregulation and structural deterioration due to high levels of inflammatory cytokines and neutrophil dysfunction, coupled with the associated activation of the RAAS and SNS. 95 Endothelial disruption and microvascular damage ultimately lead to haemodynamic derangement, and may promote astrocyte oxidative stress, consequently increasing the blood brain barrier to ammonia, worsening HE. 96 Thus, it is plausible that vasopressor agents targeting the cerebral microcirculation could be beneficial in HE, as they are in HRS.
That said, a study in acute liver failure with severe encephalopathy demonstrated worsening of cerebral hyperaemia following the administration of terlipressin. 97 Cerebral hyperaemia and increased intracranial pressure are usually associated with acute liver failure, although interestingly some patients with chronic liver disease, who undergo a transjugular intrahepatic portosystemic stent insertion, develop acute cerebral vasodilatation. This closely correlates to whole body NO production, and is thought to be driven by an iNOS dependent mechanism. 56 
| Pulmonary microcirculation
Pulmonary microvascular complications are seen in liver cirrhosis in the form of hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH). HPS is the term used for intrapulmonary microvascular dilatation resulting in impaired oxygenation in patients with liver disease and/or portal hypertension. 98 Most cases occur in advanced cirrhosis although HPS has been recognised in patients with adequate hepatic synthetic function 99 and is only manifested in 10%-17% of the overall cirrhotic population, 100, 101 Recently, it has been shown that patients with cirrhosis who recover from bacterial infections have a worse prognosis when compared to patients with similar disease severity without a history of infection. 112 Changes in the microcirculation may be responsible for this observation given that microcirculatory alterations have been shown to persist even after recovery of systemic haemodynamics in septic shock. 9 Treatment regimens involving vasoactive agents can be effective in correcting the circulatory disturbance of decompensated cirrhosis and HRS, however, a wide variability in patient response is observed, with some demonstrating little benefit. 86 While our understanding of the mechanistic action of these vasoactive agents remains somewhat limited, it is likely that they involve the microcirculation. As such, direct monitoring of the microcirculation in vivo could not only aid us to better understand the heterogeneous nature of the microcirculation in cirrhosis, but also enable us to quantify the effects of therapeutic interventions upon it, and evaluate the relationship with clinical outcomes.
| Evaluation of the microcirculation
The intrahepatic microcirculation poses several challenges to accurate measurement, including the dual blood supply of the liver, and difficult access to its vessels. Previous methods used to evaluate hepatic perfusion, include the radioactive or fluorescent microspheres technique, inert gas clearance technique and multiple indicator dilution technique. 14 These invasive techniques generally involve the introduction of a substance whose concentration is assessed following passage through the hepatic microvasculature, thus providing a surrogate measure of hepatic perfusion. Varying degrees of accuracy are seen, and their usage has been predominantly in experimental animal models or organs following post-mortem removal. [113] [114] [115] [116] In more recent times, intravital microscopy has played a pivotal role in microvascular and hepatic physiology research. 75 Video microscopy techniques that allow in vivo visualisation and measurement of the microcirculation are arguably the most useful method available today. 87 Based upon orthogonal polarisation spectroscopy, SDF and, its most recent iteration, incident dark field (IDF)
imaging, allow real time visualisation of the microvasculature at the bedside using non-invasive hand held videomicroscopes [125] [126] [127] ( Figure 2 ). Using epi-illumination, a light source is applied to the surface of an organ whereupon the light diffuses through the tissue and is subsequently reflected back by deeper tissue layers making it translucent. 128 Mucosal surfaces covered by a thin epithelial layer can also be visualised, the most common area being the easily accessible sublingual region. Numerous capillaries and venules traverse the sublingual area 129 and it has been used as a surrogate measure for the splanchnic blood flow. [130] [131] [132] Admittedly, while the sublingual region may not be representative of the state of the microcirculation in other organ systems, the ease of access makes for feasible monitoring of the extrahepatic systemic microcirculation at the bedside. 7, 74 Quantification of SDF/IDF images is standardised, reproducible and validated, allowing the functional perfusion of the microcirculation to be reliably analysed. 133 
